KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Net Cash Flow (2016 - 2025)

Resmed (RMD) has disclosed Net Cash Flow for 17 consecutive years, with $30.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 75.52% year-over-year to $30.5 million, compared with a TTM value of $848.9 million through Dec 2025, up 153.7%, and an annual FY2025 reading of $945.3 million, up 7655.27% over the prior year.
  • Net Cash Flow was $30.5 million for Q4 2025 at Resmed, down from $174.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $402.8 million in Q1 2025 and bottomed at -$81.4 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $57.8 million, with a median of $18.8 million recorded in 2022.
  • The sharpest move saw Net Cash Flow plummeted 454.16% in 2023, then soared 74796.27% in 2025.
  • Year by year, Net Cash Flow stood at -$81.4 million in 2021, then surged by 143.15% to $35.1 million in 2022, then plummeted by 120.69% to -$7.3 million in 2023, then soared by 1811.28% to $124.4 million in 2024, then plummeted by 75.52% to $30.5 million in 2025.
  • Business Quant data shows Net Cash Flow for RMD at $30.5 million in Q4 2025, $174.5 million in Q3 2025, and $241.2 million in Q2 2025.